Damora Therapeutics, Inc. (DMRA) short interest & options flow
NASDAQDamora Therapeutics heads into its November 4 earnings with two activists on its 13D register, a short position exceeding the entire free float, and retail attention running at a three-standard-deviation spike above its own 90-day history. The short interest picture here is unlike almost anything in mid-cap biotech. Shorts hold the equivalent of 365% of DMRA's free float, a reading…
DMRA short interest surges 29% in one week, hitting 403% of float—an extreme level signaling acute scarcity. Shares shorted climbed 6.5% to 5.35M on Sept 28. Availability dropped to 109%, down from 177% a week prior, tightening borrow conditions. Cost to borrow fell to 2.3%, offering little relief to bulls betting on a squeeze. CEO Jennifer Jarrett bought 12.5K shares at $20.23 on Sept 25, a modest show of conviction amid the bearish positioning.
- Market cap
- $1.42B
- Next earnings
- 11 Nov 2026
Key data as of 5 Nov 2026
DMRA news and analysis
RSSNo long-form analysis yet for DMRA. Pulse alerts and the live data picture are available on ORTEX.
Open DMRA on ORTEX →Want the live picture for DMRA?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DMRA — free to start on ORTEX.
Sign up for free →Open DMRA on ORTEX